Drug intelligence / Profile preview

IMN-005

Development stage: Preclinical
Lead developer: Immuneel Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

IMN-005 is a CAR-T cell therapy developed by Immuneel Therapeutics Pvt Ltd. It functions as an inhibitor of Fc receptor-like protein 5 (FCRL5). This investigational drug is currently in preclinical development for the treatment of hematologic neoplasms and multiple myeloma.

Targets

FCRL5 (Fc receptor-like protein 5)

Beyond the preview

Go deeper on IMN-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMN-005.

Explore the full profile